

InfuSystem Holdings, Inc
Form 10-Q
November 13, 2018

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the quarterly period ended September 30, 2018

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the transition period from _____ to _____

Commission File Number: 001-35020

INFUSYSTEM HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware **20-3341405**
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)

31700 Research Park Drive

Madison Heights, Michigan 48071

(Address of Principal Executive Offices)

(248) 291-1210

(Registrant's Telephone Number, including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Securities Exchange Act.

Large Accelerated Filer Accelerated Filer

Non-Accelerated Filer Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act). Yes No

As of November 8, 2018, 19,542,465 shares of the registrant's common stock, par value \$0.0001 per share, were outstanding.



Table of Contents

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

Index to Form 10-Q

	PAGE
PART I - <u>FINANCIAL INFORMATION</u>	
Item 1. <u>Financial Statements</u>	3
<u>-Unaudited Condensed Consolidated Balance Sheets as of September 30, 2018 and December 31, 2017</u>	3
<u>-Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2018 and 2017</u>	4
<u>-Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2018 and 2017</u>	5
<u>-Notes to the Unaudited Condensed Consolidated Financial Statements</u>	6
Item 2. <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	14
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	20
Item 4. <u>Controls and Procedures</u>	20
PART II - <u>OTHER INFORMATION</u>	
Item 1. <u>Legal Proceedings</u>	20
Item 1A. <u>Risk Factors</u>	21
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	21
Item 3. <u>Defaults Upon Senior Securities</u>	21
Item 4. <u>Mine Safety Disclosures</u>	21
Item 5. <u>Other Information</u>	21
Item 6. <u>Exhibits</u>	22
<u>Signatures</u>	23

Table of Contents**Item 1. Financial Statements****INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES****CONDENSED CONSOLIDATED BALANCE SHEETS****(UNAUDITED)**

	As of	September	December
	30,	31,	
	2018	2017	
<i>(in thousands, except share data)</i>			
ASSETS			
Current assets:			
Cash and cash equivalents	\$3,882		\$ 3,469
Accounts receivable, less allowance for doubtful accounts of \$5,769 and \$6,514 at September 30, 2018 and December 31, 2017, respectively	10,043		11,385
Inventories	1,985		1,764
Other current assets	1,303		1,049
Total Current assets	17,213		17,667
Medical equipment held for sale or rental	2,214		1,567
Medical equipment in rental service, net of accumulated depreciation	21,932		23,369
Property & equipment, net of accumulated depreciation	1,494		1,633
Intangible assets, net	21,002		24,514
Other assets	137		131
Total assets	\$63,992		\$ 68,881
LIABILITIES AND STOCKHOLDERS' EQUITY			
Current liabilities:			
Accounts payable	\$7,059		\$ 5,516
Capital lease liability, current	101		505
Current portion of long-term debt	4,775		3,039
Other current liabilities	2,727		3,414
Total current liabilities	14,662		12,474
Long-term debt, net of current portion	28,661		25,352
Capital lease liability, long-term	-		33
Deferred income taxes	62		62
Other long-term liabilities	-		7
Total liabilities	\$43,385		\$ 37,928
Stockholders' equity:			
Preferred stock, \$.0001 par value: authorized 1,000,000 shares; none issued	-		-
	2		2

Edgar Filing: InfuSystem Holdings, Inc - Form 10-Q

Common stock, \$.0001 par value: authorized 200,000,000 shares; issued and outstanding 23,050,984 and 19,565,091, respectively, as of September 30, 2018 and 22,978,398 and 22,780,738, respectively, as of December 31, 2017

Additional paid-in capital	83,058	92,584
Retained deficit	(62,453)	(61,633)
Total Stockholders' equity	20,607	30,953
Total liabilities and stockholders' equity	\$63,992	\$ 68,881

See
accompanying
notes to
unaudited
condensed
consolidated
financial
statements.

Table of Contents**INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES****CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS****(UNAUDITED)**

<i>(in thousands, except share and per share data)</i>	Three Months Ended		Nine Months Ended	
	September 30		September 30	
	2018	2017	2018	2017
Net revenues:				
Rentals	\$13,773	\$15,322	\$42,246	\$45,228
Product Sales	2,904	2,266	7,329	6,956
Net revenues	16,677	17,588	49,575	52,184
Cost of revenues:				
Cost of revenues — Product, service and supply costs	4,896	4,452	14,180	13,612
Cost of revenues — Pump depreciation and disposals	2,233	2,095	6,221	6,541
Gross profit	9,548	11,041	29,174	32,031
Selling, general and administrative expenses:				
Provision for doubtful accounts	-	1,274	-	4,456
Amortization of intangibles	1,160	1,384	3,512	4,182
Selling and marketing	2,323	2,262	6,950	7,443
General and administrative	6,160	5,561	18,423	18,451
Total selling, general and administrative	9,643	10,481	28,885	34,532
Operating (loss) income	(95)	560	289	(2,501)
Other expense:				
Interest expense	(370)	(354)	(981)	(1,015)
Other expense	(9)	(8)	(19)	(111)
(Loss) income before income taxes	(474)	198	(711)	(3,627)
(Provision for) benefit from income taxes	(45)	(327)	(109)	914
Net loss	\$(519)	\$(129)	\$(820)	\$(2,713)
Net loss per share:				
Basic and diluted	\$ (0.03)	\$ (0.01)	\$ (0.04)	\$ (0.12)
Weighted average shares outstanding:				
Basic and diluted	20,672,688	22,755,976	22,043,213	22,725,806

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

<i>(in thousands)</i>	Nine Months Ended September 30	
	2018	2017
NET CASH PROVIDED BY OPERATING ACTIVITIES	\$8,095	\$4,102
INVESTING ACTIVITIES		
Purchase of medical equipment and property	(4,962)	(2,829)
Proceeds from sale of medical equipment and property	2,900	3,518
NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES	(2,062)	689
FINANCING ACTIVITIES		
Principal payments on revolving credit facility, term loans and capital lease obligations	(5,048)	(35,769)
Cash proceeds from credit facility	9,660	28,317
Debt issuance costs	(27)	(38)
Common stock repurchased to satisfy statutory withholding on employee stock based compensation plans	(5)	(27)
Common stock repurchased as part of Repurchase Program	(10,291)	-
Cash proceeds from stock plans	91	131
NET CASH USED IN FINANCING ACTIVITIES	(5,620)	(7,386)
Net change in cash and cash equivalents	413	(2,595)
Cash and cash equivalents, beginning of period	3,469	3,398
Cash and cash equivalents, end of period	\$3,882	\$803

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies

The terms “InfuSystem”, the “Company”, “we”, “our” and “us” are used herein to refer to InfuSystem Holdings, Inc. and its subsidiaries. InfuSystem is a leading provider of infusion pumps and related services. The Company services hospitals, oncology practices and other alternative site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support, and also operates pump repair Centers of Excellence in Michigan, Kansas, California, Massachusetts and Ontario, Canada.

The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and notes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The accompanying unaudited condensed consolidated financial statements include all adjustments, composed of normal recurring adjustments, considered necessary by management to fairly state the Company’s condensed consolidated balance sheets, statements of operations and statements of cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2017 as filed with the SEC.

The unaudited condensed consolidated financial statements are prepared in conformity with GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods.

2. Revenue Recognition

Adoption of ASC 606

Except for the changes below, we have consistently applied the accounting policies to all periods in these condensed consolidated financial statements.

On January 1, 2018 the Company adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606 - Revenue from Contracts with Customers (“ASC 606”) and concluded that, consistent with prior reporting, the Company has two separate revenue streams: rentals and product sales. The adoption of ASC 606 had no impact upon adoption on the Company’s net income for the three and nine months ended September 30, 2018. However, the adoption of ASC 606 requires certain customer concessions associated with rental revenues reported in accordance with ASC 605 - Revenue Recognition, previously reported in selling, general and administrative expenses as “provisions for doubtful accounts” to now be recorded as a reduction of net rental revenues as they are considered price concessions of the transaction price under the new revenue guidance. As ASC 606 was adopted on a modified retrospective method, prior quarters are not restated.

ASC 606 defines a five-step process to recognize revenues at the time and in an amount that reflects the consideration expected to be received for the performance obligations that have been provided. ASC 606 defines contracts as written, oral and through customary business practice. Under this definition, the Company considers contracts to be created at the time that the rental service is authorized or an order to purchase product is agreed upon regardless of whether or not there is a written contract.

Performance Obligations

The Company has two separate and distinct performance obligations offered to its customers: a rental service performance obligation or a product sale performance obligation. These performance obligations are related to separate revenue streams and at no point are they combined into a single transaction.

Table of Contents

The Company generates the majority of its revenue from the rental and servicing of infusion pumps to its customers and a minority of its revenue from product sales. The Company's revenue related to rental services is recognized at the point in time that a patient concludes a treatment and the proper documentation has been received by the Company, or in certain arrangements, based on the number of pumps that a facility has onsite. The Company's revenue related to product sales is recognized at the time that control of the product has been transferred to the customer; either at the time the product is shipped or the time the product has been received by the customer depending on the shipping terms. The Company does not commit to long-term contracts to sell customers a certain minimum quantity of products.

Significant Judgments

The Company employs certain significant judgments to estimate the dollar amount of revenue, and related concessions, allocated to the rental service and sale of products. These judgments include, among others, the estimation of variable consideration. Variable consideration, specifically related to the Company's third-party payor rental revenues, is estimated as a contractual allowance for commercial payors and implied customer concessions, which has been traditionally considered bad debt for self-pay customers. The estimates for variable consideration are based on historical collections with similar payors which provide a reasonable basis for estimating the variable portion of a transaction. The Company uses the "expected value" method to estimate the component of variable consideration, which is consistent with the expectations set forth in ASC 606. The Company doesn't believe that a significant reversal of revenue will occur in future periods because (i) there is no significant uncertainty about the amount of considerations that are expected to be collected based on collection history and (ii) the large number of sufficiently similar contracts allows the Company to adequately estimate the component of variable consideration.

Financial Impact of ASC 606 Adoption

The following table presents the impact of ASC 606 on the Condensed Consolidated Statements of Operations (unaudited) for the three months ended September 30, 2018 (in thousands):

**Three Months Ended September 30,
2018**

As Reported	Adjustments	Pro-Forma as if
		Previous Accounting

			Guidance Was in Effect
Net revenues:			
Net rental revenues	\$13,773	\$ 1,467	\$ 15,240
Net revenues	16,677	1,467	18,144
Gross profit	9,548	1,467	11,015
Selling, general and administrative expenses:			
Provision for doubtful accounts	-	1,467	1,467
Total selling, general and administrative	9,643	1,467	11,110

The following table presents the impact of ASC 606 on the Condensed Consolidated Statements of Operations (unaudited) for the nine months ended September 30, 2018 (in thousands):

	Nine Months Ended September 30, 2018		
	As Reported	Adjustments	Pro-Forma as if Previous Accounting Guidance Was in Effect
Net revenues:			
Net rental revenues	\$42,246	\$ 4,804	\$ 47,050
Net revenues	49,575	4,804	54,379
Gross profit	29,174	4,804	33,978
Selling, general and administrative expenses:			
Provision for doubtful accounts	-	4,804	4,804
Total selling, general and administrative	28,885	4,804	33,689

Table of Contents

The following table presents disaggregated revenue by offering type:

	Three Months Ended September 30, 2018		Nine Months Ended September 30, 2018	
Third-Party Payor Rentals	46.8	%	47.6	%
Direct Payor Rentals	35.8	%	37.6	%
Product Sales	17.4	%	14.8	%
Total - Net revenues	100.0	%	100.0	%

3. Medical Equipment and Property

Medical equipment consists of the following (in thousands):

	September 30, 2018	December 31, 2017
Medical Equipment held for sale or rental	\$ 2,214	\$ 1,567
Medical Equipment in rental service	58,582	57,928
Medical Equipment in rental service - pump reserve	(445)	(482)
Accumulated depreciation	(36,205)	(34,077)
Medical Equipment in rental service - net	21,932	23,369
Total	\$ 24,146	\$ 24,936

Depreciation expense for medical equipment for the three and nine months ended September 30, 2018 was \$1.5 million and \$4.5 million, respectively, compared to \$1.7 million and \$4.8 million for the same prior year periods, respectively, which was recorded in “cost of revenues – pump depreciation and disposals,” for each period.

Table of Contents**4. Property and Equipment**

Property and equipment consists of the following (in thousands):

	September 30, 2018			December 31, 2017		
	Gross	Accumulated	Total	Gross	Accumulated	Total
	Assets	Depreciation		Assets	Depreciation	
Furniture, fixtures, and equipment	\$3,931	\$ (3,469)	\$462	\$3,824	\$ (3,277)	\$547
Automobiles	118	(92)	26	118	(85)	33
Leasehold improvements	2,273	(1,267)	1,006	2,187	(1,134)	1,053
Total	\$6,322	\$ (4,828)	\$1,494	\$6,129	\$ (4,496)	\$1,633

Depreciation expense for property and equipment for the three and nine months ended September 30, 2018 was \$0.1 million and \$0.3 million, respectively, compared to \$0.1 million and \$0.4 million for the same prior year periods, respectively. This depreciation expense was recorded in general and administrative expenses in the condensed consolidated statement of operations.

5. Intangible Assets

The carrying amount and accumulated amortization of intangible assets is comprised of the following (in thousands):

	September 30, 2018			December 31, 2017		
	Gross	Accumulated	Net	Gross	Accumulated	Net
	Assets	Amortization		Assets	Amortization	
Nonamortizable intangible assets						
Trade names	\$2,000	\$ -	\$2,000	\$2,000	\$ -	\$2,000
Amortizable intangible assets:						
Trade names	23	(23)	-	23	(23)	-
Physician and customer relationships	36,534	(23,582)	12,952	36,534	(21,801)	14,733
Non-competition agreements	1,136	(1,136)	-	1,136	(1,125)	11

Edgar Filing: InfuSystem Holdings, Inc - Form 10-Q

Software	11,230	(5,180)	6,050	11,230	(3,460)	7,770
Total nonamortizable and amortizable intangible assets	\$50,923	\$ (29,921)	\$21,002	\$50,923	\$ (26,409)	\$24,514

Amortization expense for the three and nine months ended September 30, 2018 was \$1.2 million and \$3.5 million, respectively, compared to \$1.4 million and \$4.2 million for the same prior year periods, respectively. Expected annual amortization expense for intangible assets recorded as of September 30, 2018 is as follows (in thousands):

	October 1					2023 and
	-					thereafter
	December	2019	2020	2021	2022	
	31, 2018					
Amortization expense	\$ 1,137	\$4,402	\$4,285	\$3,930	\$2,051	\$ 3,197

Table of Contents**6. Debt**

On July 31, 2018, the Company entered into the Fourth Amendment (the “Amendment”) to its Credit Agreement, entered into on March 23, 2015 (the “Credit Agreement”). The Amendment allows for, among other things, a loan to the Company for the repurchase of up to approximately 2.8 million shares of capital stock from an individual shareholder, his affiliates, and a second shareholder, in an aggregate amount not to exceed \$8.6 million (“Term Loan C”); and allows for capital expenditure financing to the Company for the sole purpose of purchasing medical equipment in an aggregate amount not to exceed \$6.4 million (the “Equipment Line”). There are no principal payments due on the Equipment Line until December 31, 2019 at which time it will convert to an additional term loan. The Amendment also made changes to certain covenants, specifically, to exclude borrowings used to fund the stock repurchases referenced above from the definition of fixed charges, as defined by the Credit Agreement, and to reduce the ratio of earnings before depreciation, income taxes and amortization to fixed charges from 1.25:1.0 to 1.15:1.0. In addition, the Amendment eliminates the Net Worth covenant and the excess cash flow provisions while modifying the quarterly principal payment amounts. Term Loan C matures on December 6, 2021, and the Equipment Line matures on December 31, 2024.

As of September 30, 2018, the Company’s term loans and equipment line under its credit facility had a balance of \$32.5 million and \$1.1 million, respectively. The net availability under the revolving credit line under the credit facility is based upon our eligible accounts receivable and inventory and is computed as follows (in thousands):

	September 30, 2018	December 31, 2017
Revolver:		
Gross availability	\$ 9,909	\$ 10,000
Outstanding draws	-	-
Letter of credit	(750)	(750)
Landlord reserves	(69)	(45)
Net availability	\$ 9,090	\$ 9,205

The Company had future maturities of its term loans and equipment line as of September 30, 2018 as follows (in thousands):

	2018	2019	2020	2021	2022 and thereafter	Total
Term Loans	\$1,203	\$4,813	\$4,813	\$21,671	\$ -	\$32,500
Equipment Line	-	53	212	212	583	1,060
Unamortized value of the debt issuance costs	(10)	(38)	(38)	(38)	-	(124)

Edgar Filing: InfuSystem Holdings, Inc - Form 10-Q

Total \$1,193 \$4,828 \$4,987 \$21,845 \$ 583 \$33,436

The following is a breakdown of the Company's current and long-term debt as follows (in thousands):

September 30, 2018

December 31, 2017

	Current				Current		
	Portion of	Long-Term Debt	Total		Portion of	Long-Term Debt	Total
	Long-Term Debt				Long-Term Debt		
	Debt				Debt		
Term Loans	\$ 4,813	\$ 27,687	\$32,500	Term Loans	\$ 3,067	\$ 25,444	\$28,511
Equipment Line	-	1,060	1,060	Equipment Line	-	-	-
Unamortized value of the debt issuance costs	(38)	(86)	(124)	Unamortized value of the debt issuance costs	(28)	(92)	(120)
Total	\$ 4,775	\$ 28,661	\$33,436	Total	\$ 3,039	\$ 25,352	\$28,391

Table of Contents

As of September 30, 2018, interest on the credit facility is payable at our option as a (i) Eurodollar Loan, which bears interest at a per annum rate equal to the applicable 30-day London Interbank Offered Rate (“LIBOR”) plus an applicable margin ranging from 2.00% to 3.00% or (ii) CB Floating Rate (“CBFR”) Loan, which bears interest at a per annum rate equal to the greater of (a) the lender’s prime rate or (b) LIBOR plus 2.50%, in each case, plus a margin ranging from -1.00% to 0.25%. The actual Eurodollar Loan rate at September 30, 2018 was 4.75% (LIBOR of 2.25% plus 2.50%). The actual CBFR Loan rate at September 30, 2018 was 4.75% (lender’s prime rate of 5.25% minus 0.50%).

As of September 30, 2018, the Company was in compliance with all debt-related covenants under the credit facility.

7. Income Taxes

During the three and nine months ended September 30, 2018, the Company recorded an expense provision for income taxes of less than \$0.1 million and \$0.1 million, respectively. The income tax provision relates principally to the Company’s state and local taxes and foreign operations in Canada. During the three and nine months ended September 30, 2017, the Company recorded an expense provision for income taxes of \$0.3 million and an income tax provision benefit of \$0.9 million, respectively.

The Company’s realization of its deferred tax assets is dependent upon many factors, including, but not limited to, the Company’s ability to generate sufficient taxable income. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. The Company’s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets. Accordingly, the Company had a full valuation allowance for all deferred tax assets at September 30, 2018 and December 31, 2017.

In December 2017, the Tax Cuts and Jobs Act (the “2017 Tax Act”) was enacted. The 2017 Tax Act includes many changes to existing U.S. tax laws that impact the Company, most notably a reduction of the U.S. corporate income tax rate from 35% to 21% for tax years beginning after December 31, 2017. The 2017 Tax Act also provides for a one-time transition tax on certain foreign earnings and the acceleration of depreciation for certain assets placed into service after September 27, 2017 as well as prospective changes beginning in 2018, including repeal of the domestic manufacturing deduction, acceleration of tax revenue recognition, capitalization of research and development expenditures, additional limitations on executive compensation and limitations on the deductibility of interest.

The Company recognized the income tax effects of the 2017 Tax Act in its 2017 financial statements in accordance with SEC Staff Accounting Bulletin No. 118, which provides SEC staff guidance for the application of ASC Topic 740 - Income Taxes (“ASC 740”), in the reporting period in which the 2017 Tax Act was signed into law. As such, the Company’s financial results reflect the income tax effects of the 2017 Tax Act for which the accounting

under ASC 740 is complete and provisional amounts for those specific income tax effects of the 2017 Tax Act for which the accounting under ASC 740 is not yet complete but a reasonable estimate could be determined. The ultimate impact of the 2017 Tax Act on our financial statements and related disclosures for 2018 and beyond may differ from our current provisional amounts, possibly materially, due to, among other things, changes in interpretations and assumptions we have made, guidance that may be issued and other actions we may take as a result of the 2017 Tax Act that differ from those presently contemplated.

As of September 30, 2018, the Company had not yet completed its accounting for all of the tax effects of the enactment of the 2017 Tax Act; however, the Company has made a reasonable estimate of the effects on its existing deferred tax balances. The Company will continue to refine its calculations as additional analysis is completed. The Company expects that any additional changes will be offset by a corresponding increase or decrease in the Company's valuation allowance.

8. Commitments, Contingencies and Litigation

From time to time in the ordinary course of its business, the Company may be involved in legal proceedings, the outcomes of which may not be determinable. The results of litigation are inherently unpredictable. Any claims against the Company, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. The Company is not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages and, until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. The Company has insurance policies covering potential losses where such coverage is cost effective.

Table of Contents

The Company is not involved in any legal proceedings that the Company believes could have a material effect on the Company's financial condition, results of operations or cash flows at this time.

9. Loss Per Share

Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share assumes the issuance of potentially dilutive shares of common stock during the period. The following table reconciles the numerators and denominators of the basic and diluted loss per share computations:

	Three Months Ended September 30		Nine Months Ended September 30	
	2018	2017	2018	2017
Numerator:				
Net loss (<i>in thousands</i>)	\$ (519)	\$ (129)	\$ (820)	\$ (2,713)
Denominator:				
Weighted average common shares outstanding:				
Basic	20,672,688	22,755,976	22,043,213	22,725,806
Dilutive effect of non-vested awards	-	-	-	-
Diluted	20,672,688	22,755,976	22,043,213	22,725,806
Net loss per share:				
Basic and diluted	\$ (0.03)	\$ (0.01)	\$ (0.04)	\$ (0.12)

For both the three and nine months ended September 30, 2018, 0.1 million of stock options were not included in the calculation because they would have an anti-dilutive effect, compared to 0.7 million and 0.6 million, respectively, for the same prior year periods.

10. Leases

The Company leases office space, service facility centers and equipment under non-cancelable capital and operating lease arrangements. The Company periodically enters into capital leases to finance the purchase of ambulatory infusion pumps ("Pump Assets"). The Pump Assets are capitalized into medical equipment in rental service at their fair market value, which equals the value of the future minimum lease payments and are depreciated over the useful life of the pumps. The weighted average interest rate under capital leases was 4.0% as of September 30, 2018. The leases for

office space and service facility centers used in the Company's logistics operations are operating leases. In most cases, the Company expects its facility leases will be renewed or replaced by other leases in the ordinary course of business.

Future minimum rental payments pursuant to leases that have an initial or remaining non-cancelable lease term in excess of one year as of September 30, 2018 are as follows (in thousands):

	Capital Leases	Operating Leases	Total
2018	\$ 69	\$ 411	\$480
2019	33	1,524	1,557
2020	-	938	938
2021	-	338	338
2022	-	229	229
Thereafter	-	841	841
Total required payments	\$ 102	\$ 4,281	\$4,383
Less amounts representing interest (3.5%)	(1)		
Present value of minimum lease payments	101		
Less current maturities	(101)		
Long-term capital lease liability	\$ -		

At September 30, 2018 and December 31, 2017, Pump Assets obtained under capital leases had a cost of approximately \$1.7 million, respectively, and accumulated depreciation of \$0.7 million and \$0.5 million, respectively. In the second quarter of 2018, the Company exited facility leases in Georgia and Texas and commenced a lease in Massachusetts. In accordance with ASC 420 – Exit or Disposal Activities, the Company expensed less than \$0.1 million of future lease payments relating to these exited facility leases.

Table of Contents

The Company has minimum future operating lease commitments, mainly related to its leased facilities. Associated rental expense for facilities and other equipment from third parties under operating leases for the three and nine months ended September 30, 2018 was \$0.4 million and \$1.1 million, respectively, compared to \$0.2 million and \$0.7 million for the same prior year periods, respectively.

11. Subsequent Events

The Company has evaluated subsequent events through the date of issuance for the unaudited condensed consolidated financial statements as of September 30, 2018.

12. Recent Accounting Pronouncements and Developments

In January 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-04, “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which changes the subsequent measurement of goodwill impairment by eliminating Step 2 from the impairment test. Under the new guidance, an entity will measure impairment using the difference between the carrying amount and the fair value of the reporting unit. The new standard is effective for fiscal years beginning after December 15, 2019 (i.e., a January 1, 2020 effective date), with early adoption permitted for goodwill impairment tests with measurement dates after January 1, 2017. The Company believes the adoption will not have a material impact on its consolidated balance sheets, statements of operations, statements of cash flows and related disclosures.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”. Under Topic 842, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. Topic 842 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. For public companies, Topic 842 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted. In July 2018, the FASB issued ASU 2018-10, “Codification Improvements to Topic 842, Leases”. This ASU makes various targeted amendments to the leasing standard and we are evaluating this ASU in connection with adoption of the standard. In July 2018, the FASB issued ASU 2018-11, “Leases (Topic 842): Targeted Improvements.” This standard allows entities to initially apply the new leases standard at the adoption date

and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company will adopt the standard on January 1, 2019 using the optional transition method. The standard also provides for certain practical expedients. The Company continues to evaluate and is in the process of documenting the impact of the pending adoption of the new standard on its consolidated financial position, disclosures and/or internal controls process. The Company believes the adoption of Topic 842 will result in the Company recording right-of-use assets and liabilities on the consolidated balance sheets for leases currently classified as operating leases, along with enhanced disclosures of lease activity. It is not expected that Topic 842 will have an impact on the Company's accounting for rental revenues, although that determination is still being finalized.

In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments (Topic 326) Credit Losses". Topic 326 changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. Topic 326 is effective as of January 1, 2020. Early adoption is permitted. The Company is currently evaluating the impact of Topic 326 on its consolidated balance sheets, statements of operations, statements of cash flows and related disclosures.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The terms “InfuSystem”, the “Company”, “we”, “our” and “us” used herein refer to InfuSystem Holdings, Inc. and its subsidiaries.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this quarterly report on Form 10-Q are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “strategy,” “future,” “likely,” variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. However, the absence of these words or other similar expressions does not mean that a statement is not forward-looking. In connection with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying certain factors that could cause actual results to differ, perhaps materially, from those indicated by these forward-looking statements. Those factors, risks and uncertainties include, but are not limited to, potential changes in overall healthcare reimbursement, including the Centers for Medicare and Medicaid Services (“CMS”) competitive bidding and fee schedule reductions, sequestration, concentration of customers, increased focus on early detection of cancer, competitive treatments, dependency on Medicare Supplier Number, availability of chemotherapy drugs, global financial conditions, changes and enforcement of state and federal laws, natural forces, competition, dependency on suppliers, risks in acquisitions & joint ventures, U.S. Healthcare Reform, relationships with healthcare professionals and organizations, technological changes related to infusion therapy, the Company’s ability to implement information technology improvements and to respond to technological changes, the ability of the Company to successfully integrate acquired businesses, dependency on key personnel, dependency on banking relations and the ability to comply with credit facility covenants, and other risks associated with our common stock, as well as any litigation to which the Company may be involved in from time to time; and other risk factors as discussed in the Company’s annual report on Form 10-K/A for the year ended December 31, 2017 and in other filings made by the Company from time to time with the Securities and Exchange Commission (“SEC”). Our annual report on Form 10-K/A is available on the SEC’s EDGAR website at www.sec.gov, and a copy may also be obtained by contacting the Company. All forward-looking statements made in this Form 10-Q speak only as of the date of this report. We do not intend, and do not undertake any obligation, to update any forward-looking statements to reflect future events or circumstances after the date of such statements, except as required by law.

Overview

We are a leading provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers and other sites of care from four locations in the United States and Canada. We

provide our products and services to hospitals, oncology practices and facilities and other alternate site health care providers. Headquartered in Madison Heights, Michigan, we deliver local, field-based customer support and also operate pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts and Ontario, Canada. InfuSystem, Inc., a wholly owned subsidiary of the Company, is accredited by the Community Health Accreditation Program while First Biomedical, Inc., a wholly owned subsidiary of the Company, is ISO certified.

Our core service is to supply electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics and hospital outpatient chemotherapy clinics to be utilized in the treatment of a variety of cancers including colorectal cancer and other disease states. Colorectal cancer is the third most prevalent form of cancer in the United States, according to the American Cancer Society, and the standard of care for the treatment of colorectal cancer relies upon continuous chemotherapy infusions delivered via ambulatory infusion pumps.

In addition, we sell or rent new and pre-owned pole mounted and ambulatory infusion pumps to, and provide biomedical recertification, maintenance and repair services for, oncology practices as well as other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others. We also provide these products and services to customers in the small-hospital market.

We purchase new and pre-owned pole mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis. We repair, refurbish and provide biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within our ambulatory infusion pump management service.

We view our payor environment as changing. Management is intent on extending its considerable breadth of payor contracts as patients move into different insurance coverages, including Medicaid and Insurance Marketplace products. In some cases, this may slightly reduce our aggregate billed revenues payment rate but result in an overall increase in collected revenues, effectively lessening bad debt expense on a micro level, but due to the mix of all payors may not have an impact on overall bad debt expense. Consequently, we are increasingly focused on net collected revenues less bad debt.

Table of Contents

In the midst of changes in the healthcare arena, we believe that we will support our overall business strategy discussed above by: (i) focusing on supporting recurring revenues by increasing our pump fleet; (ii) improving liquidity and strengthening the balance sheet by keeping debt levels comparable to our operations; (iii) improving internal operational efficiencies; (iv) increasing our product and services offerings; (v) enhancing our technology offerings to the patients and providers of care; and (vi) investigating synergistic acquisitions.

Results of Operations for the Three Months Ended September 30, 2018 compared to the Three Months Ended September 30, 2017

Net Revenues

Our net revenues for the quarter ended September 30, 2018 were \$16.7 million, a decrease of \$0.9 million, or 5%, compared to \$17.6 million for the quarter ended September 30, 2017. Net revenues for the quarter ended September 30, 2018 were impacted by a \$1.5 million change in recording bad debt as part of net revenue from rentals related to the implementation of Accounting Standards Codification (“ASC”) Topic 606: *Revenue from Contracts with Customers* (“ASC 606”) on a modified retrospective approach effective January 1, 2018. Absent the implementation of ASC 606, total net revenues for the quarter ended September 30, 2018 would have been \$18.1 million, an increase of \$0.6 million, or 3%, compared to \$17.6 million in the same prior year period. The majority of the increase for the quarter was attributable to net revenues from product sales.

During the quarter ended September 30, 2018, net revenues from rentals decreased \$1.5 million, or 10%, compared to the same prior year period. Absent the implementation of ASC 606, net revenues from rentals for the quarter ended September 30, 2018 would have decreased \$0.1 million, or 1%, compared to the same prior year period. This decrease was primarily attributable to a slight decrease in claims billed to third-party payors during the quarter ended September 30, 2018 compared to the same prior year period. Net revenues from product sales for the quarter ended September 30, 2018 were \$2.9 million, an increase of \$0.6 million, or 28%, compared to the same prior year period. The increase in product sales was primarily the result of increased disposable sales of \$0.3 million and equipment sales of \$0.3 million.

Gross Profit

Gross profit for the quarter ended September 30, 2018 was \$9.5 million, a decrease of \$1.5 million, or 14%, compared to the quarter ended September 30, 2017. As a percentage of revenues, gross profit for the quarter ended September 30, 2018 was 57%, down from the same prior year period of 63%. Gross profit for the quarter ended September 30, 2018 was impacted by a \$1.5 million change in recording bad debt as part of net revenue from rentals related to the implementation of ASC 606. Absent the implementation of ASC 606, gross profit for the quarter ended September 30,

2018 would have been \$11.0 million, which was consistent with the amount recorded for the comparable prior year period. Absent the implementation of ASC 606, gross profit, as a percentage of revenues, for the quarter ended September 30, 2018 would have been 61%, down from the same prior year period of 63%. The decrease was due to lower margins on selective disposable supply sales, as well as increased labor costs on pump servicing due to demand for selective pumps and the need to increase turnaround time on delivery of these pumps.

Provision for Doubtful Accounts

Due to the implementation of ASC 606, the Company did not record any provision for doubtful accounts (“Bad Debt”) for the quarter ended September 30, 2018 compared to Bad Debt of \$1.3 million for the quarter ended September 30, 2017. Absent the implementation of ASC 606, Bad Debt for the quarter ended September 30, 2018 would have been \$1.4 million, an increase of \$0.2 million, or 13%, compared to the same prior year period. Absent the net difference of credits taken to the accrual in the third quarters of 2018 and 2017, respectively, the provision would have decreased by \$0.1 million.

Amortization of Intangible Assets

Amortization of intangible assets for the quarter ended September 30, 2018 was \$1.2 million, a decrease of \$0.2 million compared to the same prior year period, attributable to the impairment of certain internally developed, internal-use software assets that was recorded in the fourth quarter of 2017; therefore, the related amortization of those projects no longer existed during 2018.

Selling and Marketing Expenses

Selling and marketing expenses for the quarter ended September 30, 2018 were \$2.3 million, an increase of \$0.1 million, or 3%, compared to the same prior year period. This increase was primarily attributable to an increase in travel and related costs primarily due to company-wide initiatives.

Table of Contents

General and Administrative Expenses

General and administrative expenses for the quarter ended September 30, 2018 were \$6.2 million, an increase of \$0.6 million, or 11%, from \$5.6 million for the quarter ended September 30, 2017. The increase in general and administrative expenses versus the comparable prior year period was primarily due to increases in employee compensation related expenses of \$0.4 million and legal and shareholder costs of \$0.3 million, partially offset by a decrease in outside services expense of \$0.1 million. The increase in employee compensation expenses was primarily attributable to a \$0.2 million increase in stock compensation expense, a \$0.1 million net increase in incentive bonus accrual and \$0.1 million of salaries and related expenses.

Other Income and Expenses

Other expenses for the quarter ended September 30, 2018 were \$0.4 million, which was consistent with the amount recorded for the comparable prior year period.

Income Taxes

During the quarter ended September 30, 2018, the Company recorded a provision for income taxes of less than \$0.1 million. The income tax provision relates principally to the Company's state and local taxes and foreign operations in Canada. During the quarter ended September 30, 2017, the Company recorded a provision for income taxes of \$0.3 million.

Results of Operations for the Nine Months Ended September 30, 2018 compared to the Nine Months Ended September 30, 2017

Net Revenues

Our net revenues for the nine months ended September 30, 2018 were \$49.6 million, a decrease of \$2.6 million, or 5%, compared to \$52.2 million for the same prior year period. Net revenues for the nine months ended September 30, 2018 were impacted by a \$4.8 million change in recording bad debt as part of net revenue from rentals related to the implementation of ASC 606. Absent the implementation of ASC 606, total net revenues for the nine months ended September 30, 2018 would have been \$54.4 million, an increase of \$2.2 million, or 4%, compared to \$52.2 million in

the same prior year period. This increase was primarily driven by an increase in net revenues from rentals (absent implementation of ASC 606) for the nine months ended September 30, 2018.

During the nine months ended September 30, 2018, net revenues from rentals decreased \$3.0 million, or 7%, compared to the same prior year period. Absent the implementation of ASC 606, net revenues from rentals for the nine months ended September 30, 2018 would have increased \$1.8 million, or 4%, compared to the same prior year period. This increase was primarily attributable to the Company's ongoing program to expand its number of third-party payors under contract, thereby increasing our net reimbursement rate, and the Company's efforts to reduce claims rejected by third-party payors. Net revenues from product sales for the nine months ended September 30, 2018 were \$7.3 million, an increase of \$0.4 million, or 5%, compared to the same period of 2017. This increase was primarily the result of an increase in disposable sales of \$0.5 million and accessory sales of \$0.1 million, which was offset by a decrease in equipment sales of \$0.2 million.

Gross Profit

Gross profit for the nine months ended September 30, 2018 was \$29.2 million, a decrease of \$2.9 million, or 9%, compared to the same prior year period. As a percentage of revenues, gross profit for the nine months ended September 30, 2018 was 59%, down from 61% for the same prior year period. Gross profit for the nine months ended September 30, 2018 was impacted by a \$4.8 million change in recording bad debt as part of net revenue from rentals related to the implementation of ASC 606. Absent the implementation of ASC 606, gross profit for the nine months ended September 30, 2018 would have been \$34.0 million, an increase of \$1.9 million, or 6%, compared to \$32.0 million in the same prior year period. This increase was driven mainly by the increase in net revenues absent the implementation of ASC 606, as well as an improvement in profitability over the prior year. Absent the implementation of ASC 606, gross profit, as a percentage of revenues, for the nine months ended September 30, 2018 would have been 62%, up from 61% in the same prior year period. Profitability was helped by lower incremental costs for pumps sold expense, product and supply costs (net of the third quarter 2018 margin decrease) and pump rental expense.

Provision for Doubtful Accounts

Due to the implementation of ASC 606, the Company did not record any Bad Debt for the nine months ended September 30, 2018 compared to \$4.5 million for the same prior year period. Absent the implementation of ASC 606, Bad Debt for the nine months ended September 30, 2018 would have been \$4.7 million, an increase of \$0.2 million, or 5%, compared to the same prior year period. Absent the net difference of credits taken to the accrual in the third quarters of 2018 and 2017, respectively, the provision would have decreased by \$0.1 million.

Table of Contents

Amortization of Intangible Assets

Amortization of intangible assets for the nine months ended September 30, 2018 was \$3.5 million, a decrease of \$0.7 million compared to the same prior year period. This decrease is attributable to the impairment of some internally developed, internal-use software assets that was recorded in the fourth quarter of 2017; therefore, the related amortization of those projects no longer existed during 2018.

Selling and Marketing Expenses

Selling and marketing expenses for the nine months ended September 30, 2018 were \$6.9 million, a decrease of \$0.5 million, compared to \$7.4 million for the same prior year period. The decrease was largely attributable to a decrease in salaries and related expenses of \$0.6 million, which was partially offset by an increase of \$0.1 million related to travel & related expenses. Selling and marketing expenses during these periods consisted of sales personnel salaries, commissions and associated fringe benefit and payroll-related items, marketing, share-based compensation, overall travel and entertainment and other miscellaneous expenses.

General and Administrative Expenses

General and administrative expenses for the nine months ended September 30, 2018 were \$18.4 million, a decrease of less than \$0.1 million compared to the same prior year period. The decrease in general and administrative expenses versus the comparable prior year period was primarily due to decreases in outside services expense of \$0.7 million and capital lease retirement charges of \$0.3 million, partially offset by an increase in employee compensation related expenses of \$0.7 million and legal and shareholder costs of \$0.2 million. The increase in employee compensation related expenses was primarily attributable to a \$0.7 million net increase in the incentive bonus accrual, \$0.4 million of salaries and related expenses and \$0.2 million of stock compensation expense. These increases were partially offset by a \$0.6 million decrease in severance expenses.

Other Income and Expenses

Other expenses for the nine months ended September 30, 2018 and 2017 were \$1.0 million and \$1.1 million, respectively. The decrease included a less than \$0.1 million decrease in interest expense primarily due to repayments of long-term debt.

Income Taxes

During the nine months ended September 30, 2018, the Company recorded a provision for income taxes of \$0.1 million. The income tax provision relates principally to the Company's state and local taxes and foreign operations in Canada. During the nine months ended September 30, 2017, the Company recorded a benefit from income taxes of \$0.9 million, due mainly to the temporary timing differences of expenses recorded compared to when they will be deductible.

The Company's realization of its deferred tax assets is dependent upon many factors, including, but not limited to, the Company's ability to generate sufficient taxable income. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. The Company's management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets. Accordingly, the Company had a full valuation allowance for all deferred tax assets at September 30, 2018 and December 31, 2017.

In December 2017, the Tax Cuts and Jobs Act (the "2017 Tax Act") was enacted. The 2017 Tax Act includes many changes to existing U.S. tax laws that impact the Company, most notably a reduction of the U.S. corporate income tax rate from 35% to 21% for tax years beginning after December 31, 2017. The 2017 Tax Act also provides for a one-time transition tax on certain foreign earnings and the acceleration of depreciation for certain assets placed into service after September 27, 2017 as well as prospective changes beginning in 2018, including repeal of the domestic manufacturing deduction, acceleration of tax revenue recognition, capitalization of research and development expenditures, additional limitations on executive compensation and limitations on the deductibility of interest.

Table of Contents

The Company recognized the income tax effects of the 2017 Tax Act in its 2017 financial statements in accordance with Staff Accounting Bulletin No. 118, which provides SEC staff guidance for the application of ASC Topic 740 - Income Taxes (“ASC 740”), in the reporting period in which the 2017 Tax Act was signed into law. As such, the Company’s financial results reflect the income tax effects of the 2017 Tax Act for which the accounting under ASC 740 is complete and provisional amounts for those specific income tax effects of the 2017 Tax Act for which the accounting under ASC 740 is not yet complete, but a reasonable estimate could be determined. The ultimate impact of the 2017 Tax Act on our financial statements and related disclosures for 2018 and beyond may differ from our current provisional amounts, possibly materially, due to, among other things, changes in interpretations and assumptions we have made, guidance that may be issued and other actions we may take as a result of the 2017 Tax Act that differ from those presently contemplated.

As of September 30, 2018, the Company had not yet completed its accounting for all of the tax effects of the enactment of the 2017 Tax Act; however, the Company has made a reasonable estimate of the effects on its existing deferred tax balances. The Company will continue to refine its calculations as additional analysis is completed. The Company expects that any additional changes will be offset by a corresponding increase or decrease in the Company’s valuation allowance.

Liquidity and Capital Resources

Overview:

We finance our operations and capital expenditures with internally generated cash from operations and borrowings under our credit facility. As of September 30, 2018, we had cash and cash equivalents of \$3.9 million and \$9.1 million of availability on our revolving credit facility compared to \$3.5 million of cash and cash equivalents and \$9.2 million of availability on our revolving credit facility at December 31, 2017. Our liquidity and borrowing plans are established to align with our financial and strategic planning processes and ensure we have the necessary funding to meet our operating commitments, which primarily include the purchase of pumps, inventory, payroll and general expenses. We also take into consideration our overall capital allocation strategy which includes investment for future growth, share repurchases and potential acquisitions. We believe we have adequate sources of liquidity and funding available for at least the next year, however, there are a number of factors that may negatively impact our available sources of funds. The amount of cash generated from operations will be dependent upon factors such as the successful execution of our business plan and general economic conditions.

Long-Term Debt Activities:

On July 31, 2018, the Company entered into the Fourth Amendment (the “Amendment”) to its Credit Agreement, entered into on March 23, 2015 (the “Credit Agreement”). The Amendment allows for, among other things, a loan to the Company for the repurchase of up to approximately 2.8 million shares of capital stock from an individual shareholder, his affiliates, and a second shareholder, in an aggregate amount not to exceed \$8.6 million (“Term Loan C”); and allows for capital expenditure financing to the Company for the sole purpose of purchasing medical equipment in an aggregate amount not to exceed \$6.4 million (the “Equipment Line”). There are no principal payments due on the Equipment Line until December 31, 2019 at which time it will convert to an additional term loan. The Amendment also made changes to certain covenants, specifically, to exclude borrowings used to fund the stock repurchases referenced above from the definition of fixed charges, as defined by the Credit Agreement, and to reduce the ratio of earnings before depreciation, income taxes and amortization to fixed charges from 1.25:1.0 to 1.15:1.0. In addition, the Amendment eliminates the Net Worth covenant and the excess cash flow provisions while modifying the quarterly principal payment amounts. Term Loan C matures on December 6, 2021, and the Equipment Line matures on December 31, 2024.

As of September 30, 2018, our term loans and equipment line under the credit facility had balances of \$32.5 million and \$1.1 million, respectively. The net availability under the revolving credit line under the credit facility is based upon our eligible accounts receivable and inventory and is computed as follows (in thousands):

	September 30, 2018	December 31, 2017
Revolver:		
Gross availability	\$ 9,909	\$ 10,000
Outstanding draws	-	-
Letter of credit	(750)	(750)
Landlord reserves	(69)	(45)
Net availability	\$ 9,090	\$ 9,205

As of September 30, 2018, interest on the credit facility is payable at our option as a (i) Eurodollar Loan, which bears interest at a per annum rate equal to the applicable 30-day London Interbank Offered Rate (“LIBOR”) plus an applicable margin ranging from 2.00% to 3.00% or (ii) CB Floating Rate (“CBFR”) Loan, which bears interest at a per annum rate equal to the greater of (a) the lender’s prime rate or (b) LIBOR plus 2.50%, in each case, plus a margin ranging from -1.00% to 0.25%. The actual Eurodollar Loan rate at September 30, 2018 was 4.75% (LIBOR of 2.25% plus 2.50%). The actual CBFR Loan rate at September 30, 2018 was 4.75% (lender’s prime rate of 5.25% minus 0.50%).

Table of Contents

As of September 30, 2018, the Company was in compliance with all debt-related covenants under the credit facility.

Share Repurchase Program

On March 12, 2018, our Board of Directors approved a stock repurchase program authorizing the Company to repurchase up to one million shares of the Company's outstanding common stock (the "Share Repurchase Program"). Repurchases under the repurchase program will be subject to market conditions, the periodic capital needs of the Company's operating activities, and the continued satisfaction of all covenants under the Company's existing Credit Agreement. As of September 30, 2018, we had availability of \$9.1 million under our credit facility, of which \$8.5 million could be used to fund stock repurchases, subject to the restrictions and limitations of our Credit Agreement. The repurchase program does not obligate the Company to repurchase shares and may be suspended, terminated, or modified at any time. Repurchases under the program may take place in the open market or in privately negotiated transactions and may be made under a Rule 10b5-1 plan.

The Company has repurchased approximately 0.5 million shares under the Share Repurchase Program through September 30, 2018 in addition to the approximately 2.1 million shares repurchased under the First Stock Purchase Agreement (as defined below) and approximately 0.7 million shares repurchased under the Second Stock Purchase Agreement (as defined below). This total of approximately 3.3 million shares represents a 14% reduction in the shares outstanding at December 31, 2017.

Stock Purchase and Settlement Agreement and Stock Purchase Agreement

On July 31, 2018, the Company and an individual shareholder and his affiliates (the "Sellers") entered into a stock purchase and settlement agreement (the "First Stock Purchase Agreement") for the purchase by the Company of the approximately 2.2 million shares of the Company's common stock cumulatively owned by the Sellers for \$3.10 per share, equaling approximately \$6.7 million in total. The First Stock Purchase Agreement contains customary representations and warranties, an agreement by the Sellers not to purchase any shares of the Company's common stock for three years following closing, a mutual non-disparagement agreement and a mutual release of claims between the Company and the Sellers. The closing of the stock purchases under the First Stock Purchase Agreement occurred in full during the third quarter of 2018 with respect to approximately 2.1 million shares, and the Sellers sold approximately 36,000 of the remaining shares to third parties on the open market. The Company funded the purchase price for the shares with the proceeds from the Term Loan C described above.

On July 31, 2018, the Company and a shareholder entered into a stock purchase agreement (the "Second Stock Purchase Agreement") for the purchase by the Company of approximately 0.7 million shares of the Company's common stock owned by a shareholder for \$3.10 per share, equaling approximately \$2.1 million in total. The Second

Stock Purchase Agreement contains customary representations and warranties, and the closing of the stock purchases under the stock purchase agreement occurred during the third quarter of 2018. The Company funded the purchase price for the shares with the proceeds from the Term Loan C described above and cash-on-hand.

Cash Flows:

Operating Cash Flow. Net cash provided by operating activities for the nine months ended September 30, 2018 was \$8.1 million compared to net cash provided by operating activities of \$4.1 million for the nine months ended September 30, 2017. This increase was primarily attributable to the cash flow effect of the operating improvement resulting in a reduced net loss for the nine months ended September 30, 2018 compared to the nine months ended September 30, 2017, the impact of non-cash transactions, including deferred income taxes and amortization of intangibles, and the increased change in liabilities.

Investing Cash Flow. Net cash used in investing activities was \$2.1 million for the nine months ended September 30, 2018 compared to cash provided by investing activities of \$0.7 million for the nine months ended September 30, 2017. The decrease was due to a \$2.2 million increase in cash used to purchase medical equipment and a \$0.6 million decrease in cash proceeds from the sales of medical equipment.

Financing Cash Flow. Net cash used in financing activities for the nine months ended September 30, 2018 was \$5.6 million compared to net cash used in financing activities of \$7.4 million for the nine months ended September 30, 2017. The decrease in net cash used was primarily attributable to our decision to pay down our term loan debt in the first half of 2018 and the repurchase of common stock compared with our cash proceeds from borrowings under our revolving credit facility during the nine months ended September 30, 2017 and the decision to pay down a majority of our capital lease obligations during the first half of 2017.

Table of Contents

Critical Accounting Policies and Estimates

The unaudited condensed consolidated financial statements are prepared in conformity with U.S. Generally Accepted Accounting Principles, which require the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, due to inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods. The critical accounting estimates that affect the unaudited condensed consolidated financial statements and the judgments and assumptions used are consistent with those described in the notes to the audited consolidated financial statements in our annual report on Form 10-K/A for the year ended December 31, 2017, with the exception of our adoption of ASC 606. See Note 2 to the accompanying unaudited condensed consolidated financial statements for further details.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

InfuSystem is a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and is not required to provide the information required under this item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures and Changes in Internal Control over Financial Reporting

We maintain a set of disclosure controls and procedures designed to ensure that material information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that material information is accumulated and communicated to our management, including our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), as appropriate, to allow timely decisions regarding required disclosures. Our CEO and CFO have evaluated these disclosure controls and procedures as of the end of the period covered by this quarterly report on Form 10-Q and have determined that such disclosure controls and procedures were effective.

Our new Chief Financial Officer is assessing, and will continue to assess, the Company's disclosure controls and procedures and internal controls over financial reporting.

There has been no change in our internal control over financial reporting during our most recent calendar quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

From time to time in the ordinary course of our business, we may be involved in legal proceedings, the outcomes of which may not be determinable. The results of litigation are inherently unpredictable. Any claims against us, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. We are not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages and until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. We have insurance policies covering potential losses where such coverage is cost effective.

We are not at this time involved in any legal proceedings that we believe could have a material effect on our business, financial condition, results of operations or cash flows.

Table of Contents**Item 1A. Risk Factors**

For information regarding factors that could affect our results of operations, financial condition and liquidity, refer to the section entitled “Risk Factors” in Part I, Item 1A in our Annual Report on Form 10-K/A for the year ended December 31, 2017.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The table below provides information with respect to common stock purchases by the Company during the nine months ended September 30, 2018:

Period	Total Number of Shares Purchased (a)	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (b)	Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs (b)
March 12, 2018 - March 31, 2018	32,264	\$ 2.57	32,264	\$ 2,417,012
April 1, 2018 - April 30, 2018	39,878	2.74	39,878	2,307,857
May 1, 2018 - May 31, 2018	23,400	2.91	23,400	2,239,717
June 1, 2018 - June 30, 2018	285,000	3.13	285,000	1,348,717
July 1, 2018 - July 31, 2018	31,303	3.20	31,303	1,248,675
August 1, 2018 - August 31, 2018	2,834,689	3.10	48,119	1,097,661
September 1, 2018 - September 30, 2018	41,699	3.31	41,699	959,684
Total	3,288,233	\$ 3.10	501,663	

(a) In addition to the 501,663 shares repurchased as part of the Share Repurchase Program during the nine months ended September 30, 2018, the Company also repurchased approximately 2,100,000 and 700,000 shares as part of

the First and Second Stock Purchase Agreements, respectively, which are included in the total number of shares purchased in the table above.

- (b) On March 12, 2018, our Board of Directors authorized a Share Repurchase Program that allows the Company to repurchase up to the lesser of 1,000,000 shares or \$2,500,000 of our common stock through December 31, 2018. The repurchases are to be effectuated in the open market or in privately negotiated transactions and may be made under a Rule 10b5-1 plan. During the nine months ended September 30, 2018, we repurchased 501,663 shares for a total consideration of \$1,540,316 under the program. At September 30, 2018, \$959,684 remains available for repurchase under the program.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Table of Contents

Item 6. Exhibits

Exhibits

- 31.1* Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 31.2* Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32.1* Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
- 32.2* Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
- 101.INS* XBRL Instance Document
- 101.SCH* XBRL Taxonomy Extension Schema Document
- 101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document
- 101.DEF* XBRL Taxonomy Extension Definition Linkbase Document
- 101.LAB* XBRL Taxonomy Extension Label Linkbase Document
- 101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith

** Pursuant to Item 601(b)(32) of Regulation S-K, this Exhibit is furnished rather than filed with the Form 10-Q.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INFUSYSTEM HOLDINGS, INC.

/s/ Richard DiIorio

Date: November 13, 2018

Richard DiIorio
Chief Executive Officer, President and Director

(Principal Executive Officer)

/s/ Gregory Schulte

Date: November 13, 2018

Gregory Schulte
Chief Financial Officer

(Principal Financial Officer)